Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
Hjerpe A.,Karolinska University Hospital |
Ascoli V.,University of Rome La Sapienza |
Bedrossian C.W.M.,Rush University |
Boon M.E.,Leiden Cytology and Pathology Laboratory |
And 13 more authors.
Diagnostic Cytopathology | Year: 2015
Objective To provide practical guidelines for the cytopathologic diagnosis of malignant mesothelioma. Data Sources Cytopathologists with an interest in the field involved in the International Mesothelioma Interest Group (IMIG) and the International Academy of Cytology (IAC) contributed to this update. Reference material includes peer-reviewed publications and textbooks. Rationale This article is the result of discussions during and after the IMIG 2012 conference in Boston, followed by thorough discussions during the 2013 IAC meeting in Paris. Additional contributions have been obtained from cytopathologists and scientists who could not attend these meetings, with final discussions and input during the IMIG 2014 conference in Cape Town. Diagn. Cytopathol. 2015;43:563-576. © 2015 Wiley Periodicals, Inc.
McDonnell A.M.,University of Western Australia |
Prosser A.C.,University of Western Australia |
Van Bruggen I.,University of Western Australia |
Robinson B.W.S.,University of Western Australia |
And 2 more authors.
European Journal of Immunology | Year: 2010
One of the clear paradoxes in tumor immunology is the fact that cross-presentation of cell-associated tumor antigens to CD8+ T cells is efficient, yet CTL generation is weak, and tumors continue to grow. We examined, for the first time whether this may be due to alterations in the phenotype or function of cross-presenting DC using a solid tumor model expressing a membrane bound neo-antigen (hemagglutinin, HA). Tumor antigen was constitutively cross-presented in the tumor-draining LN throughout tumor progression by CD11c+ DC. Further analysis revealed that both CD8α+ and CD8α- DC subsets, but not plasmacytoid DC, were effective at cross-presenting HA tumor antigen. The proportions of DC subsets in the tumor-draining LN were equivalent to those seen in the LN of naïve mice; however, a significant increase in the expression of the potential inhibitory B7 molecule, B7-DC, was noted and appeared to be restricted to the CD8α- DC subset. Therefore LN resident CD8α+ DC are not the sole DC subset capable of cross-presenting cell-associated tumor antigens. Migratory tumor DC subsets with altered co-stimulatory receptor expression may contribute to induction and regulation of tumor-specific responses. © 2010 Wiley-VCH Verlag GmbH & Co. KGaA.